Chemomab Therapeutics and Scipher Medicine to Merge to Advance Nebokitug in AI-Powered RA Trial
July 9, 2026
Chemomab Therapeutics and Scipher Medicine have announced a definitive merger agreement in a stock transaction. The combined company, expected to operate as Scipher Medicine Corporation and trade on Nasdaq, will initially focus on advancing Chemomab’s nebokitug into a Phase 2 rheumatoid arthritis trial using Scipher’s AI Network Medicine platform and PrismRA test.
- Buyers
- Scipher Medicine
- Targets
- Chemomab Therapeutics
- Industry
- Healthcare Services
- Location
- Israel
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Scancell Holdings Merges With Neuphoria Therapeutics Under $89 Million Financing Plan
July 24, 2026
Biotechnology
Scancell Holdings and Neuphoria Therapeutics have entered an all-share merger agreement in which Scancell will acquire Neuphoria. The combined company is expected to operate under the Scancell name and list on Nasdaq, alongside Scancell’s existing AIM listing, and finance the transaction with up to $89 million in equity and debt.
-
TandemAI Merges with Perpetual Medicines to Expand Peptide and AI Drug Discovery Capabilities
July 10, 2025
Biotechnology
TandemAI and Perpetual Medicines have merged, with the combined company operating under the TandemAI name. Perpetual Medicines will operate as a separate entity within TandemAI to extend the firm's capabilities into computational peptide design and integrated synthesis, while leadership from both companies will continue in senior roles; financial terms were not disclosed.
-
Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio
December 11, 2024
Biotechnology
Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.
-
GlycoMimetics to Acquire Crescent Biopharma (Merger to Operate as Crescent Biopharma, Inc.)
October 29, 2024
Healthcare Services
GlycoMimetics entered into an acquisition agreement with privately held oncology-focused biotechnology company Crescent Biopharma. The combined company will operate under the name Crescent Biopharma, Inc., advancing Crescent’s precision-engineered biologics for solid tumors, including the lead program CR-001, alongside ADC programs CR-002 and CR-003, supported by approximately $200 million in committed financing. GlycoMimetics stockholders approved the proposed merger in June 2025, and the combined company is expected to begin trading on Nasdaq on June 16, 2025 under the new ticker.
-
Adaptimmune Therapeutics And TCR² Therapeutics To Merge (All-Stock)
March 6, 2023
Healthcare Services
Adaptimmune Therapeutics plc and TCR² Therapeutics Inc announced they have entered into a definitive agreement to merge in an all-stock transaction, combining to form a preeminent cell therapy company focused on solid tumors. The merged company will leverage complementary engineered T-cell technology platforms (SPEAR and TRuC) and is expected to extend its cash runway into 2026 following closing.
-
Scipher Medicine Acquires CrossBridge to Add Real-time Patient Data and Analytics Platform
January 10, 2023
Data & Analytics
Scipher Medicine has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data management and analytics capabilities. The acquisition (closed; terms not disclosed) adds CrossBridge's SaaS value-based care platform to enable real-time mapping of patient molecular, clinical and claims data and to support Scipher's precision immunology offerings such as the PrismRA test.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.